Comparison of Fixed-dose Rosiglitazone/Metformin Combination Therapy with Sulphonylurea Plus Metformin in Overweight Individuals with Type 2 Diabetes Inadequately Controlled on Metformin Alone

 

 Buy Article Permissions and Reprints

Abstract

Aim: This 52-week, randomized, double-blind, parallel-group study was designed to compare rosiglitazone/metformin fixed-dose combination therapy with combination sulphonylurea plus metformin therapy in overweight individuals with inadequately controlled type 2 diabetes mellitus.

Method: Individuals with inadequate glycaemic control (HbA_1c≥7%) while on metformin monotherapy (≥0.85 g/day) entered a 4-week run-in period during which they received metformin 2 g/day. At the end of the run-in, individuals with fasting plasma glucose ≥7.0 mmol/l were randomized to treatment with metformin (2 g/day) and either rosiglitazone (4 mg/day; RSG+MET [N=294]) or a sulphonylurea (glibenclamide 5 mg/day or gliclazide 80 mg/day; SU+MET [N=302]). Medications were up-titrated to maximum tolerated doses (rosiglitazone 8 mg, glibenclamide 15 mg or gliclazide 320 mg plus metformin 2 g/day) during the first 12 weeks of double-blind treatment. The primary efficacy end point was the change in HbA_1c from baseline after 52 weeks of treatment.

Results: RSG+MET was non-inferior to SU+MET with respect to changes in HbA_1c after one year of treatment (ΔHbA_1c=-0.78% and -0.86%, respectively; treatment difference =0.09%, 95% CI=-0.08, 0.25). The HbA_1c reductions with RSG+MET, but not SU+MET, were accompanied by significant improvements in measures of β-cell function including proinsulin:insulin ratio. The degree of β-cell failure was significantly greater with SU+MET compared to RSG+MET as measured by the coefficient of failure (0.543 vs. 0.055 HbA_1c%/year, respectively, p=0.0002). The proportion of individuals who experienced hypoglycaemic events was significantly (p<0.0001) lower with RSG+MET (6%) than with SU+MET (30%). Diastolic ambulatory blood pressure and cardiovascular biomarkers (high-sensitivity C-reactive protein and plasminogen activator inhibitor-1) were also reduced following one year of treatment with RSG+MET but not SU+MET. Both treatments were generally well tolerated.

Conclusion: Fixed-dose combination therapy with rosiglitazone/metformin is non-inferior to sulphonylurea plus metformin combination therapy in reducing HbA_1c over one year of treatment. Improvements in measures of β-cell function suggest that the improvements in glycaemic control may be better maintained in long-term therapy with the rosiglitazone/metformin combination.

References

• 1 Bailey CJ, Bagdonas A, Rubes J, MacMorn SO, Donaldson J, Biswas N, Stewart MW. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes: a 24-week, randomized, double-blind, parallel-group study.  Clin Ther. 2005;  27 1548-1561
  CrossrefPubMedGoogle Scholar
• 2 Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes.  Diabetes Care. 2004;  27 1535-1540
  CrossrefPubMedGoogle Scholar
• 3 Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N, Doddrell DM. Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients.  Obes Res. 2002;  10 1008-1015
  CrossrefPubMedGoogle Scholar
• 4 Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.  Diabetologia. 2005;  48 1093-1104
  CrossrefPubMedGoogle Scholar
• 5 Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.  JAMA. 2000;  283 1695-1702
  CrossrefPubMedGoogle Scholar
• 6 Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.  Diabetes Obes Metab. 2006;  8 156-163
  CrossrefPubMedGoogle Scholar
• 7 Garber AJ, Bruce S, Fiedorek FT. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.  Clin Ther. 2002;  24 1401-1413
  CrossrefPubMedGoogle Scholar
• 8 Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.  Circulation. 2002;  106 679-684
  CrossrefPubMedGoogle Scholar
• 9 Jones TA, Sautter M, Gaal LF Van, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.  Diabetes Obes Metab. 2003;  5 163-170
  CrossrefPubMedGoogle Scholar
• 10 Kahn SE, Haffner S, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G. for the ADOPT Study Group . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.  N Engl J Med. 2006;  355 2427-2443
  CrossrefPubMedGoogle Scholar
• 11 Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD, Sachara C, Pfutzner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.  Circulation. 2005;  111 2525-2531
  CrossrefPubMedGoogle Scholar
• 12 Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes.  J Clin Endocrinol Metab. 2001;  86 280-288
  CrossrefPubMedGoogle Scholar
• 13 Linnemann B, Voigt W, Nobel W, Janka HU. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome.  Exp Clin Endocrinol Diabetes. 2006;  114 127-134
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones.  Drugs. 2002;  62 1463-1480
  CrossrefPubMedGoogle Scholar
• 15 Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.  Diabetes. 2002;  51 797-802
  CrossrefPubMedGoogle Scholar
• 16 Miyazaki Y, Matsuda M, Mahankali A, Mahankali S, Cusi K, Mandarino L, DeFronzo R. Mechanisms of glucose-lowering effect by rosiglitazone in patients with type 2 diabetes.  Diabetes. 2001;  50 ((Suppl 2)) A126
  PubMedGoogle Scholar
• 17 Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, Al Haddad W, Dhindsa S, Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone.  J Clin Endocrinol Metab. 2004;  89 2728-2735
  CrossrefPubMedGoogle Scholar
• 18 Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.  Diabetes Care. 2004;  27 1349-1357
  CrossrefPubMedGoogle Scholar
• 19 Pfutzner A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T, Lubben G, Forst T. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes.  Diabetes Care. 2004a;  27 682-687
  CrossrefPubMedGoogle Scholar
• 20 Pfutzner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer study.  J Am Coll Cardiol. 2005;  45 1925-1931
  CrossrefPubMedGoogle Scholar
• 21 Pfutzner A, Pfutzner AH, Larbig M, Forst T. Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus.  Diabetes Technol Ther. 2004b;  6 405-412
  CrossrefPubMedGoogle Scholar
• 22 Scheen AJ. Glitazones and weight gain.  Annales D'Endocrinologie. 2002;  63 IS412-IS414
  PubMedGoogle Scholar
• 23 Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.  Diabetes Care. 1997;  20 597-606
  CrossrefPubMedGoogle Scholar
• 24 Smith SA, Porter LE, Biswas N, Freed MI. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes.  J Clin Endocrinol Metab. 2004;  89 6048-6053
  CrossrefPubMedGoogle Scholar
• 25 Stenman S, Melander A, Groop PH, Groop LC. What is the benefit of increasing the sulfonylurea dose?.  Ann Intern Med. 1993;  118 169-172
  PubMedGoogle Scholar
• 26 The DREAM (Diabetes REduction Assessment with ramipril, rosiglitazone Medication) trial investigators . Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.  Lancet. 2006;  368 1096-1105
  CrossrefPubMedGoogle Scholar
• 27 Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.  JAMA. 1999;  281 2005-2012
  CrossrefPubMedGoogle Scholar
• 28 UK Prospective Diabetes Study (UKPDS) Group . UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease.  Diabetes. 1995;  44 1249-1258
  CrossrefPubMedGoogle Scholar
• 29 UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet. 1998a;  352 854-865
  CrossrefPubMedGoogle Scholar
• 30 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998b;  352 837-853
  CrossrefPubMedGoogle Scholar
• 31 Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.  Curr Med Res Opin. 2006;  22 751-759
  CrossrefPubMedGoogle Scholar
• 32 Wallace TM, Matthews DR. Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes.  Diabet Med. 2002;  19 465-469
  CrossrefPubMedGoogle Scholar
• 33 World Health Organization . Diabetes mellitus. 1999; 
  PubMed

Correspondence

Prof. Dr. med. A. Hamann

Abteilung Innere Medizin I und Klinische Chemie

Universitätsklinikum Heidelberg

Im Neuenheimer Feld 410

69120 Heidelberg

Germany

Phone: +49/6221/56 86 03

Fax: +49/6221/56 40 36

Email: andreas_hamann@med.uni-heidelberg.de